Dr. Phoebe Joy Ho is presenting the results of the CAMMA 3 trial, which evaluates cevostamab in relapsed/refractory #myeloma (#RRMM), at #ASH2025.

The NoMoreMGUS study was presented today at #ASH25. 5,000 people with #MGUS were enrolled in this Spanish study to better understand who may progress and how to improve monitoring. Watch the key results explained by Bruno Paiva, Clínica Universidad de Navarra, Spain. www.youtube.com/watch?v=ORkR...

Yesterday at #ASH25 we heard data from the GEM-CESAR trial, studying early rescue treatment with daratumumab, pomalidomide and dexamethasone in high-risk smoldering #myeloma. Watch the key results explained by Bruno Paiva (Clínica Universidad de Navarra). youtu.be/jDoP3xCL8IE?...

Juan Du MD presenting interesting results on AZD0120 dual targeting (BCMA/CD19) CAR-T using FasTCAR manufacturing. #myeloma #CAR-T

Iberdomide is a CELMoD drug being explored in #myeloma. Niels Van De Donk highlighted @emnmyeloma.bsky.social #EMN26 Phase 2 data on use as a post transplant maintenance therapy in NDMM. #ASH25

MPE is at #ASH2025, starting with #myeloma oral session on MRD and maintenance therapy, double hit HR-MM, iberdomide, carfilzomb and sonrotoclax treatments.

MPE starts #ASH2025 by presenting APCL Cares, a comprehensive psychosocial support programme developed by the Portuguese Association Against Leukaemia (APCL).

MPE is attending the @ash.hematology.org annual congress in Orlando, Florida. Over the next few days, we will follow the key updates in #myeloma and #ALamyloidosis and speak with leading experts to understand what they mean for patients. #ASH25